Carfentanil Is Back in the Drug Supply. More Than 1 in 10 Fentanyl Samples Now Test Positive.

Carfentanil — the veterinary tranquilizer roughly 10,000 times stronger than morphine that briefly swept through parts of the illicit opioid supply in 2016 before largely disappearing — is back. Labcorp’s June 2026 drug trends report, which analyzes samples from clinical and forensic toxicology testing nationwide, found carfentanil present in more than 10% of fentanyl-positive specimens. In 2021 and 2022, that number was near zero.

The reappearance matters for anyone who uses drugs, anyone who carries naloxone, and any harm reduction program that is calibrating its overdose response protocols. Carfentanil is not just a more potent fentanyl. It is categorically different in how quickly it produces respiratory depression and how resistant it can be to standard naloxone reversal doses. Multiple doses of naloxone may be required to reverse a carfentanil overdose — meaning the standard advice to “give one spray and wait” is potentially life-threatening when carfentanil is in the mix.

The mechanism is straightforward: carfentanil binds to the same mu-opioid receptors that fentanyl targets, but with roughly 100 times fentanyl’s affinity and potency. Someone who has been using what they believe is fentanyl, and who has calibrated their own dose accordingly, has no pharmacological early warning that what they received this week is not what they received last week. The overdose appears identical — until it isn’t, and naloxone either works or requires far more of it than the person nearby happened to carry.

The national overdose numbers have improved: CDC preliminary data shows approximately 69,147 projected drug overdose deaths for the 12 months ending January 2026, a 13.2% decline from the previous year. That trend was earned, in part, by the expansion of naloxone access — over-the-counter availability, wide distribution through harm reduction programs, and community saturation in heavily affected areas. Carfentanil’s return puts pressure on that progress in a specific way: it may not increase the total number of overdoses immediately, but it is likely to increase the proportion of overdoses that don’t reverse on the first dose.

Compounding the picture: nitazenes and orphines — a separate class of synthetic opioids with potencies matching or exceeding fentanyl — have been detected in more than a dozen states, per a June 2026 investigation in Time. Unlike fentanyl, many nitazene analogs are not detectable with fentanyl test strips, which were already restricted from SAMHSA grant funding in April. People who use drugs are navigating a supply that is simultaneously more dangerous and harder to screen.

The practical implications for anyone carrying naloxone: carry more. Have multiple doses — ideally two to four doses of 4mg intranasal naloxone, or injectable naloxone if available. Don’t use alone. And if you’re working in harm reduction: update your reversal guidance. The standard “one dose, wait two minutes, repeat if needed” protocol remains correct — but the emphasis on “repeat if needed” needs to be louder.